People

  1. Sklarin
    Sklarin
  2. Jeong
    Jeong
  3. Keller
    Keller
  4. Bott
    Bott
  5. Ma
    Ma
  6. Won
    Won
  7. Ho
    Ho
  8. Schoder
    Schoder
  9. Nafa
    Nafa
  10. Parker
    Parker
  11. Kantoff
    Kantoff
  12. Haimovitz-Friedman
    Haimovitz-Friedman
  13. Fagin
    Fagin
  14. Tamari
    Tamari
  15. Beal
    Beal

Recent Works

  1. Patient-centered outcomes in ARIEL3, a phase 3, randomized, placebo-controlled study of rucaparib maintenance treatment in patients with recurrent ovarian carcinoma
    Meeting Abstract

    Bedel, D. J.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J. I.; Clamp, A. R.; Scambia, G.; Leary, A.; more...
    Value in Health (2019)

    Fulltext@MSK | Save
  2. Cost-effectiveness of a 24-month fixed duration of venetoclax in combination with rituximab in relapsed or refractory chronic lymphocytic leukemia in the United States
    Meeting Abstract

    Huntington, S. F.; Strunz-McKendry, T.; Masaquel, A. S.; Shapouri, S.; Sail, K.; Durno, N.; Mato, A.
    Value in Health (2019)

    Fulltext@MSK | Save
  3. Quality adjusted time without symptoms of disease progression or toxicity (Q-TWIST) of nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) among untreated advanced renal cell carcinoma (ARCC) patients (patients) with intermediate or poor prognostic risk
    Meeting Abstract

    Shah, R.; Botteman, M.; Kwon, Y.; Gooden, K. M.; Cella, D.; Motzer, R.
    Value in Health (2019)

    Fulltext@MSK | Save